Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multicenter, Nonrandomized, Open-Label, Single-Arm, Phase 4 Study

Abstract

Background Global phase III trials demonstrated efficacy of abemaciclib in patients with HR +/HER2– metastatic breast cancer (BC) as a first-line therapy in combination with a nonsteroidal aromatase inhibitor (MONARCH-3) or with fulvestrant following progression after endocrine therapy (ET) (MONARCH-2). However, there is limited data on safety and tolerability of abemaciclib plus ET in the metastatic BC setting among Indian patients, which the present study aims to address.

Materials and Methods An open-label, single-arm, phase IV study was conducted across 16 centers in India to assess the safety and tolerability of abemaciclib in patients with HR +/HER2– locally advanced or metastatic BC. Patients were assigned to either cohort A, ET-naive patients (abemaciclib + anastrozole/letrozole) or cohort B, patients progressing after previous ET (abemaciclib + fulvestrant), targeting the same patient population as the global phase III MONARCH-3 and MONARCH-2 trials, respectively. Primary endpoints were all-cause adverse events (AEs) including serious AEs (SAEs).

Statistical Analysis The statistical analysis was conducted using SAS Version 9.4.

Results Two hundred patients were enrolled, with a mean age of 54 years, most (77.0%) were aged ≤ 65 years. The median duration of exposure was similar in both cohorts (cohort A vs. B: 24.3 vs. 24.4 weeks). Overall, 75.5 % of patients reported all-cause AEs, of which 38.5% of the patients reported AEs Common Terminology Criteria for Adverse Events grade 3 and above. The most common grade 3 and above all-cause AEs for abemaciclib were neutropenia (19.0%), followed by anemia (14.0%) and diarrhea (5.5%). Fourteen (7.0%) patients encountered SAEs, including infections (2.0%) and gastrointestinal disorders (1.5%). Most of the patients continued their treatments with appropriate dose reductions (25.5%) and dose omissions (40.5%), and only 2.5% of patients discontinued study treatment due to treatment-related AEs.

Conclusion Abemaciclib in combination with ET was found to have an acceptable tolerability in Indian patients with HR +/HER2– advanced and metastatic BC, consistent with the established safety data as reported in the pivotal global studies. No new clinical safety concerns were identified, with most of the reported AEs and SAEs managed by dose adjustments.

Keywords

breast cancer - endocrine therapy - CDK4/6 inhibitors - abemaciclib - advanced breast cancer - India

Authors' Contributions

All authors contributed significantly to the study. D.C.D., T.M., R.N., S.C.T., R.T., S.P., A.T. M., M.J., D.M., P.N.M. and S.G. were involved in the acquisition and interpretation of data, critical revision of the manuscript, and approval of the final version of the manuscript. S.G. also contributed to the acquisition and interpretation of data, critical revision of the manuscript, and approval of the final version. K.N.S. played a key role in interpreting the results, preparing the manuscript draft, and approving the final version. A.P. and R.A. contributed to the conception and design of the study, interpretation of the data, critical revision of the manuscript, and approval of the final version. All authors have approved the final manuscript.

Ethical Approval and Statement of Conforming to the Declaration of Helsinki

The study's protocol (I3Y-IN-JPEC) received approval from the ethics committees of all the participating centers. It adhered to ethical principles from international guidelines such as the Declaration of Helsinki, the Council for International Organizations of Medical Sciences (CIOMS), and the International Conference on Harmonisation's (ICH) Good Clinical Practice (GCP) guidelines, in addition to relevant laws and regulations (Clinicaltrials.gov - NCT04707196; Clinical Trials Registry - India (CTRI) - CTRI/2020/12/030021). All patients provided written informed consent before enrollment.

Publikationsverlauf

Eingereicht: 16. September 2024

Angenommen: 07. Januar 2025

Artikel online veröffentlicht:
31. Januar 2025

• References

• 1 WHO. Breast cancer: Globocan 2022: World Health Organization: International Agency for research on Cancer. Accessed March 13, 2024 at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf
• 2 WHO. India: Globocan 2022. Accessed March 13, 2024 at: https://gco.iarc.who.int/media/globocan/factsheets/populations/356-india-fact-sheet.pdf
• 3 Mehrotra R, Yadav K. Breast cancer in India: present scenario and the challenges ahead. World J Clin Oncol 2022; 13 (03) 209-218
• 4 Sathishkumar K, Sankarapillai J, Mathew A. et al. Breast cancer survival in India across 11 geographic areas under the National Cancer Registry Programme. Cancer 2024; 130 (10) 1816-1825
• 5 Gogia A, Deo SVS, Sharma D. et al. Clinicopathologic characteristics and treatment outcomes of patients with up-front metastatic breast cancer: single-center experience in India. J Glob Oncol 2019; 5: 1-9
• 6 Cardoso F, Senkus E, Costa A. et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol 2018; 29 (08) 1634-1657
• 7 Flaum LE, Gradishar WJ. Advances in endocrine therapy for postmenopausal metastatic breast cancer. Cancer Treat Res 2018; 173: 141-154
• 8 Meegdes M, Geurts SME, Erdkamp FLG. et al. Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2- metastatic breast cancer: an observational study of the SONABRE Registry. Lancet Reg Health Eur 2023; 26: 100573
• 9 Gennari A, André F, Barrios CH. et al; ESMO Guidelines Committee. Electronic address: [e-mail]. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021; 32 (12) 1475-1495
• 10 Guidelines®) NCCN Clinical Practice Guidelines in Oncology (NCCN). Breast Cancer 2023. Accessed January 16, 2025 at: www.nccn.org/patients
• 11 Burstein HJ, Somerfield MR, Barton DL. et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO Guideline update. J Clin Oncol 2021; 39 (35) 3959-3977
• 12 Tolaney SM, Beeram M, Beck JT. et al. Abemaciclib in combination with endocrine therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a phase 1b study. Front Oncol 2022; 11: 810023
• 13 FDA. FDA approves abemaciclib for HR-positive, HER2-negative breast cancer 2017. Accessed March 20, 2024 at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-hr-positive-her2-negative-breast-cancer
• 14 Patnaik A, Rosen LS, Tolaney SM. et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov 2016; 6 (07) 740-753
• 15 Dickler MN, Tolaney SM, Rugo HS. et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR⁺/HER2⁻ metastatic breast cancer. Clin Cancer Res 2017; 23 (17) 5218-5224
• 16 Sledge Jr GW, Toi M, Neven P. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017; 35 (25) 2875-2884
• 17 Torres-Guzmán R, Calsina B, Hermoso A. et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. Oncotarget 2017; 8 (41) 69493-69507
• 18 Gelbert LM, Cai S, Lin X. et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 2014; 32 (05) 825-837
• 19 Sledge Jr GW, Toi M, Neven P. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 2020; 6 (01) 116-124
• 20 Goetz MP, Toi M, Huober J. et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol 2024
• 21 Johnston S, Martin M, Di Leo A. et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 2019; 5: 5
• 22 Zhang QY, Sun T, Yin YM. et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol 2020; 12: 17 58835920963925
• 23 CDSCO. List of new drugs approved in the year 2019 till date 2019. Accessed March 13, 2024 at: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadApprovalNewDrugs/ndedec13appro.pdf
• 24 Takahashi M, Tokunaga E, Mori J. et al. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer 2022; 29 (01) 174-184
• 25 Lee KWC, Lord S, Finn RS. et al. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat 2019; 174 (01) 271-278
• 26 Goetz MP, Toi M, Campone M. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017; 35 (32) 3638-3646
• 27 Rugo HS, Huober J, García-Sáenz JA. et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist 2021; 26 (01) e53-e65
• 28 Parikh PM, Amish V, Rajan Y. et al. Consensus guidelines for the use of cyclin-dependent kinase (CDK) 4/6 inhibitors in the management of hormone receptor positive (HR+ ve), Her2− ve early breast cancer (EBC). South Asian J Cancer 2024
• 29 Kaur M. Dietary intake, prevalence, and the effect of anemia on various morphophysiological variables of postmenopausal women of North India. J Midlife Health 2018; 9 (02) 72-78